0000019584-26-000012
SEC filingQ1 revenue grew 1.6% to $657.5M as VITAS offset Roto-Rooter service declines, but profitability declined due to gross margin contraction and operating expense pressure, partially mitigated by strong operating cash flow of $88.2M.
Gross profit edged down to $215.8 million from $216.4 million, resulting in a gross margin of 32.8%, reflecting pressure from variable costs in patient care and other operational factors. Operating income declined more sharply by 10.7% to $84.6 million from $94.8 million, producing an operating margin of 12.9%. This contraction highlights the impact of higher operating expenses relative to revenue growth, consistent with the company's dual-segment model where service volume fluctuations affect profitability.
Net income fell 7.6% to $66.3 million from $71.8 million, with diluted EPS at $4.84 versus $4.86 prior year. Despite profitability challenges, cash generation remained robust, with net cash provided by operating activities surging to $88.2 million from $32.7 million. After $17.1 million in capital expenditures (up from $13.3 million), free cash flow reached $71.1 million. This strong liquidity supports management's ongoing evaluation of capital allocation alternatives, including share repurchases, debt management, acquisitions, and dividend increases to maximize shareholder value.
Overall, Q1 demonstrates resilience in cash flow amid profitability headwinds, positioning Chemed to pursue growth and returns while navigating segment and external challenges.